ProPhase Labs, Inc. Q1 FY2025 earnings call

• Ted Karkus discussed turning around the company, having taken over as an activist shareholder and turning around previous struggling aspects like the Cold-EEZE brand. - They sold Pharmaloz for $23 million in January, shut down an unprofitable lab in February, reduced headcount from 96 to 25, and Ted and other executives deferred compensation. - Discussed NASDAQ listing status, expecting a 6-month extension as they meet all qualifications except stock price. - BE-Smart esophageal cancer test has multibillion-dollar potential, with a paper submitted to a journal and aiming for commercialization later this year. - Nebula Genomics is being put up for sale, with a clean business now operating at or near breakeven, having a large genomic dataset and subscription model. - Crown Medical collections potential, with expectations of settlements from insurance companies underpaying for COVID testing. - Equivir capsules' final results awaited, with commercialization targeted for the next cough/cold season.

The company's segments include ProPhase Biopharma (featuring the BE-Smart Esophageal Cancer Test), Nebula Genomics, and ProPhase supplements. Nebula Genomics is a potential liquidity event, and the BE-Smart test has multibillion-dollar potential in its target market of endoscopies for high-risk esophageal cancer patients. However, specific absolute revenue figures and contribution percentages for each segment aren't detailed in absolute terms but are discussed in terms of their potential and current status.

• Anticipates liquidity events soon, including potential sale of Nebula Genomics within 3-4 months. - Believes BE-Smart esophageal cancer test could be commercialized on a patient basis later this year. - Expectations of Crown Medical collections in the next couple of months, which could be a significant cash inflow. - Hopes that once liquidity events occur, the company will be in a stronger financial position, avoiding dilutive financings for commercialization of BE-Smart.

• Risks related to obtaining and maintaining regulatory approvals. - General economic conditions and consumer demand for products and services. - Challenges in entering and growing new business lines. - Competitive environment. - NASDAQ listing risk if stock price remains under $1 beyond the 6-month extension period. - Uncertainties in collecting all accounts receivable from COVID testing, though confident in collecting a significant amount.

Q: What's a realistic time line we should expect to see BE-Smart commercialized? Will it be this year?

A: Ted Karkus said it depends on definition of commercialization, anticipates first patient testing on a commercial basis later this year but is methodical and won't overpromise.

Q: Specifically, what vaccines or illnesses are we working on? And is anything past clinical studies?

A: Not working on vaccines, not spending much on FDA drug development. Working on Equivir, awaiting final results; BE-Smart esophageal cancer test in submission phase for peer review.

Q: What steps are being taken to meet NASDAQ compliance? Will you need to file for an extension?

A: Ted said they meet all NASDAQ qualifications except stock price, expect a 6-month extension when the first 6 months expire next month as they meet all other criteria.

Q: Has the DNA Complete division started generating revenues?

A: Yes, DNA Complete has developed into a more sophisticated direct-to-consumer product generating about $5 million a year in revenues, with potential to grow with marketing spend if capital allows.

Q: Are we still looking at June/July for COVID testing payments?

A: Ted said it's possible to get first payments in June, with confidence a significant amount of capital will come in the second half of the year though timing is uncertain.

Q: You announced an agreement with a global private equity group for debt financing. Have you accessed the line of credit yet?

A: Yes, took in a small amount of capital with shares as collateral, currently looking at other debt financing sources to bridge to liquidity events.

Q: What are the milestone items shareholders should be aware of for the balance of 2025?

A: Key milestones include liquidity events from Crown Medical collections and Nebula Genomics sale, development of BE-Smart test, and Equivir commercialization.

Q: Does the company still have a high degree of confidence in collecting the $25 million of uncollected AR?

A: Confident in collecting what's on the books, hopeful to collect significantly more, and believes BE-Smart test has huge potential in the market.

Q: If and when we receive payment for past due COVID testing, think smaller dividend and more cash in the bank. I hold position of nearly 200,000 shares.

A: Ted agreed, stating he wants to be shareholder-friendly, anticipates new debt financing shortly, and looks forward to being home free once liquidity events occur.

Q: How do you plan to bring up the stock price?

A: Ted believes stock price will take care of itself with cash inflows, mentioned past success with Dutch auctions and being shareholder-friendly, and anticipates commercialization of BE-Smart and other initiatives will help boost the stock price.

Q: Can you tell us what you are going to do with the funds you get in from Crown Medical or possibly selling Nebula?

A: Ted said he'll play it by ear, aiming for shareholder-friendly decisions, and anticipates commercializing BE-Smart without large expenses and potential partnerships or acquisitions for the test.

Q: What happened to Equivir?

A: Equivir's final results awaited as consultants and CROs are in communication, with commercialization targeted for the next cough/cold season, though frustrated with the delay.

Q: What is the forward-looking prospectus from here?

A: Ted expects to get through debt financing shortly, anticipates liquidity events from Crown Medical collections and Nebula Genomics sale within months, and is bullish on the company's future with initiatives like BE-Smart commercialization.